Brief: Lexeo Therapeutics Announces License Agreement To Accelerate Development Of LX2006
22/04/2024 12:38
April 22 (Reuters) - Lexeo Therapeutics Inc LXEO.O :
* LEXEO THERAPEUTICS ANNOUNCES LICENSE AGREEMENT TO
ACCELERATE
DEVELOPMENT OF LX2006 FOR THE TREATMENT OF FRIEDREICH ATAXIA
CARDIOMYOPATHY
* LEXEO THERAPEUTICS INC: INTERIM READOUT OF COMBINED DATA
SET AT
MULTIPLE DOSES EXPECTED MID-YEAR 2024
* LEXEO THERAPEUTICS INC: INTERIM READOUT OF COMBINED DATA
SET AT
MULTIPLE DOSES EXPECTED MID-YEAR 2024
* LEXEO THERAPEUTICS: IN-LICENSE AGREEMENT WITH CORNELL
UNIVERSITY
* LEXEO THERAPEUTICS: IN-LICENSE AGREEMENT WITH CORNELL
UNIVERSITY
Source text for Eikon: ID:nGNX9hbGJV
Further company coverage: LXEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease